ER-100 has entered a Phase 1 eye-disease trial. This is a safety milestone for partial epigenetic reprogramming, not approval or proof of whole-body age reversal.
NAD+ biology is relevant to brain aging research, but no human trial has shown that NAD+ therapy prevents, slows, or reverses Alzheimer's or Parkinson's disease.
A buyer-focused review of senolytics in 2026: what human trials actually found, why dasatinib plus quercetin is not routine anti-aging care, and what to verify before considering a clinic protocol.
ARPA-H's PROSPR program funds seven teams with up to $144 million. Here is what the program is testing, what its milestones mean, and why it is not yet validation of a healthspan treatment.
UT Health San Antonio described a multi-phase rapamycin project and a separate short recruitment study. Here is what each protocol tests, what remains unknown, and what the announcement does not prove.
The Nature Metabolism review found sparse human tissue data and limited clinical efficacy. Three 2026 studies add narrow signals, but do not establish NAD+ interventions as general longevity treatments.
